Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Epizyme Inc (EPZM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,038,875
  • Shares Outstanding, K 69,490
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -134,310 K
  • 36-Month Beta 2.09
  • Price/Sales 110.14
  • Price/Cash Flow N/A
  • Price/Book 4.81

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.50 +2.41%
on 06/18/18
18.70 -20.59%
on 05/24/18
-2.15 (-12.65%)
since 05/18/18
3-Month
12.56 +18.23%
on 04/24/18
19.55 -24.04%
on 03/27/18
-3.90 (-20.80%)
since 03/16/18
52-Week
11.15 +33.18%
on 08/01/17
21.40 -30.61%
on 03/13/18
+1.20 (+8.79%)
since 06/16/17

Most Recent Stories

More News
Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA)

-- Consistently High Responses in Patients with an EZH2 Activating Mutation

EPZM : 14.85 (-0.67%)
First Week of July 20th Options Trading For Epizyme (EPZM)

Investors in Epizyme Inc. saw new options become available this week, for the July 20th expiration.

EPZM : 14.85 (-0.67%)
Why Is Epizyme (EPZM) Up 16.2% Since Its Last Earnings Report?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EPZM : 14.85 (-0.67%)
Report: Developing Opportunities within Silicon Motion Technology, Green Brick Partners, Alliance Resource Partners, Perrigo Company plc, Epizyme, and Landec -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Silicon Motion Technology Corporation...

LNDC : 14.10 (-1.40%)
GRBK : 12.18 (-0.61%)
ARLP : 19.55 (-2.01%)
SIMO : 51.00 (+2.39%)
EPZM : 14.85 (-0.67%)
PRGO : 74.36 (-1.00%)
Epizyme Presents Encouraging Phase 2 Data of Tazemetostat for Malignant Mesothelioma at ASCO

-- Represents the First Reported Clinical Data of an EZH2 Inhibitor in Patients with Relapsed/Refractory Malignant Mesothelioma

EPZM : 14.85 (-0.67%)
Epizyme to Host Investor Conference Call to Discuss Interim Follicular Lymphoma Clinical Data

Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call at 8:30 a.m. ET on June 15, 2018 to discuss interim...

EPZM : 14.85 (-0.67%)
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1

Epizyme (EPZM) betters loss estimates in Q1 and expects to file a new drug application to the FDA for its lead pipeline candidate tazemetostat in fourth-quarter 2018.

PTGX : 7.25 (+1.26%)
LGND : 193.49 (+0.95%)
RHHBY : 26.3900 (-0.94%)
EPZM : 14.85 (-0.67%)
Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss

Epizyme posted narrower-than-expected loss in the first quarter of 2018. However, the company reported no revenues during the period.

EPZM : 14.85 (-0.67%)
Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates

Enrollment of Patients Completed in Multiple Tazemetostat Combination Studies

EPZM : 14.85 (-0.67%)
Is a Beat in Store for Epizyme (EPZM) This Earnings Season?

Epizyme (EPZM) is expected to provide updates on pipeline candidates when it reports Q1 results on May 8.

KERX : 5.04 (+0.60%)
ADVM : 5.55 (unch)
RHHBY : 26.3900 (-0.94%)
EPZM : 14.85 (-0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade EPZM with:

Business Summary

Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 15.35
1st Resistance Point 15.10
Last Price 14.85
1st Support Level 14.55
2nd Support Level 14.25

See More

52-Week High 21.40
Fibonacci 61.8% 17.48
Fibonacci 50% 16.27
Fibonacci 38.2% 15.07
Last Price 14.85
52-Week Low 11.15

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar